Valpione Sara, Campana Luca G
Christie Hospital NHS Foundation Trust, 550 Wilmslow Rd, Manchester, M20 4BX, UK.
Department of Surgery, Oncology & Gastroenterology, University of Padova, via Gattamelata 64, 35128 Padova, Italy.
Immunotherapy. 2016 Feb;8(2):199-209. doi: 10.2217/imt.15.111. Epub 2016 Jan 25.
As calculated by the meta-analysis of Korn et al., the prognosis of metastatic melanoma in the pretarget and immunological therapy era was poor, with a median survival of 6.2 and a 1-year life expectancy of 25.5%. Nowadays, significant advances in melanoma treatment have been gained, and immunotherapy is one of the promising approaches to get to durable responses and survival improvement. The aim of the present review is to highlight the recent innovations in melanoma immunotherapy and to propose a critical perspective of the future directions of this enthralling oncology subspecialty.
正如科恩等人的荟萃分析所计算的那样，在靶向治疗和免疫治疗时代之前，转移性黑色素瘤的预后很差，中位生存期为6.2个月，1年预期生存率为25.5%。如今，黑色素瘤治疗已取得显著进展，免疫疗法是实现持久缓解和提高生存率的有前景的方法之一。本综述的目的是强调黑色素瘤免疫疗法的最新创新，并对这一引人入胜的肿瘤学亚专业的未来方向提出批判性观点。
